Edis Mesic
Staff Reporter
Edis Mesic covers the Yale School of Medicine for the SciTech desk. He is a first year in Saybrook from San Jose, California.
Author Archive
Yale research may pave way for diagnostic tests and vaccines for tick-borne diseases

The team created a novel tick antigen library housing over 3,000 different proteins, testing each to create a target cocktail for a potential anti-tick vaccine.

Yale researchers use machine learning to predict PTSD symptoms

Machine learning model, developed by researchers, has a relatively high prediction strength for clinical measures.

Yale School of Medicine achieves 100 percent match rate

All 87 medical school students who enrolled into the process were matched into a residency program in 2025.

Yale scientists design personalized cancer vaccine

The News reached out to the scientists to discuss their research journey and the vaccine’s impacts.

Yale researchers developed AI tool to predict heart muscle disease

The model can screen for signs of cardiomyopathies that medical professionals may not be able to detect.

Inside Yale’s medical school: First years share their experiences

The News talked to first-year students at the School of Medicine about the pre-clerkship curriculum and non-academic opportunities.

First FDA-approved non-addictive painkiller has Yale roots

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Yale researchers develop AI tool that predicts risk of heart failure

The artificial intelligence model predicts patients’ heart disorders and risk of future heart failure using just an electrocardiogram.

Yale multidisciplinary heart team first in Connecticut to perform BATMAN procedure

Members of the team spoke with the News about their experiences performing the BATMAN procedure and its future implications.

Yale team ranked second in biodiversity monitoring competition, earns $2 million prize

Map of Life team members built a species distribution database and later used it to develop new global biodiversity monitoring technologies.

Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal

Modifi Bio’s founders discuss the journey from developing a cancer treatment drug to being acquired by Big Pharma.